New treatment improves survival in first-line small cell lung cancer with a combination of tarlatamab and durvalumab, showing a significant clinical benefit.
Axogen acquires BioCircuit Technologies in a $200M deal to expand its peripheral nerve repair offerings and market position.
Generative AI regulation takes center stage as the FDA unveils its strategy, tackling approval pathways, safety standards, industry…
New treatment improves survival in first-line small cell lung cancer with a combination of tarlatamab and durvalumab, showing…
Hospitals face steep CAR T-cell therapy costs, from drug pricing to staffing and safety protocols, straining smaller clinics…
tozorakimab COPD therapy shows significant reduction of inflammation by targeting multiple pathways, offering new hope beyond eosinophil‑focused treatments.
Eosinophil guided steroid reduction in COPD cuts ICS doses without raising severe flare‑ups, according to the COPERNICOS trial…
The FDA approves camizestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Learn about this new treatment…
Adjunct antipsychotics are emerging as a promising option for treating depression when antidepressants fall short, offering new hope…
Cancer telehealth is bridging the vast distance barrier for Mountain West patients, offering remote specialist access and reducing…
Evolocumab reduces heart attack risk by 20% in high-risk patients with atherosclerosis or diabetes, lowering mortality rates effectively.
